Inavolisib + Ribociclib + Fulvestrant for Breast Cancer

This trial tests a new treatment combination for individuals with advanced breast cancer resistant to hormone therapy. The study compares the effects of adding inavolisib, a potential cancer treatment, to the existing treatments ribociclib and fulvestrant, against using a placebo instead of inavolisib. It seeks to determine if this new combination is more effective and safe for patients whose cancer is hormone receptor-positive, lacks the PIK3CA genetic mutation, and has a specific chromosome loss (chromosome 8p). This trial may suit someone whose breast cancer has spread, cannot be treated with surgery or radiation, and no longer responds to hormone therapy. As a Phase 2 trial, it focuses on measuring the treatment's effectiveness in an initial, smaller group, allowing participants to contribute to important research.

The trial information does not specify if you need to stop taking your current medications. However, if you have Type 2 diabetes requiring ongoing treatment, you may not be eligible to participate.

Research has shown that the combination of inavolisib, ribociclib, and fulvestrant for treating advanced breast cancer appears safe. An early safety report found that patients generally tolerated this combination well. Most side effects were mild or moderate, with common ones being tiredness, nausea, and diarrhea. These side effects are typical for cancer treatments and can usually be managed.

Inavolisib and ribociclib are key parts of this treatment. Ribociclib is already approved for some breast cancers, so its safety is well-known. Although inavolisib is still under study, current data suggests it is safe when used with ribociclib and fulvestrant.

Researchers are excited about the combination of inavolisib, ribociclib, and fulvestrant for breast cancer because it introduces a novel approach to treatment. Unlike standard therapies that often target hormone receptors alone, inavolisib works by inhibiting the PI3K pathway, which is frequently activated in breast cancer and contributes to tumor growth and resistance. This combination aims to tackle cancer more effectively by simultaneously blocking multiple pathways that tumors use to survive and grow. By combining these drugs, there's potential for improved outcomes for patients who might not respond to existing treatments.

In this trial, participants will receive either a combination of inavolisib, ribociclib, and fulvestrant or a placebo with ribociclib and fulvestrant. Research has shown that the combination of inavolisib, ribociclib, and fulvestrant may effectively treat a certain type of advanced breast cancer. In one study, patients who received this combination lived for a median of 34 months, compared to 27 months for those who received a different treatment. These findings suggest that the three-drug therapy might help people live longer with this type of cancer. While more research is needed, these early results offer hope for those facing this challenging condition.²³⁴⁵⁶